Table Info

Table 1.

Inclusion and exclusion criteria used to identify participants in the study

Inclusion criteria	Exclusion criteria
Moderately severe asthmatics Aged 12 and above On ICS/LABA therapy On ICS dose < 800 mcg BDP equivalent	Mild asthmatics Aged below 12 years old On SABA only, ICS only or ICS/LABA/LAMA Asthma COPD overlap Asthmatics with ILD On ICS dose > 800 mcg BDP equivalent

ICS: inhaled corticosteroid; LABA: long-acting beta-agonist; SABA: short-acting β₂-agonist; LAMA: long-acting muscarinic antagonist; BDP: beclomethasone dipropionate; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease

Declarations

Author contributions

SH: Conceptualization, Project administration, Resources, Validation, Visualisation, Writing—original draft, Writing—review & editing. EG and JR: Investigation, Resources. SG: Conceptualization, Data curation, Formal analysis, Resources, Methodology, Validation, Visualisation, Writing—review & editing.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study was approved by the De Montfort University Institutional Review Board Faculty Research Ethics Committee (FREC/019-68) and complies with the Declaration of Helsinki.

Consent to participate

Informed consent to participate in this study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher. However, data sets will be anonymised to maintain patient confidentiality.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

2022 GINA Report, Global Strategy for Asthma Management and Prevention [Internet]. Fontana: Global Initiative for Asthma – GINA; c2024 [cited 2024 Aug 26]. Available from: https://ginasthma.org/gina-reports/

Vaswani A, Khaw HJ. Medicine in a minute. Branbury: Scion Publishing Ltd; 2018.

Asthma Statistics [Internet]. British Lung Foundation; c2023 [cited 2024 Aug 26]. Available from: https://irp.cdn-website.com/672be0a6/files/uploaded/Asthma%20statistics%20_%20British%20Lung%20Foundation.html

Asthma [Internet]. World Health Organization; c2024 [cited 2024 Aug 27]. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma

Castillo JR, Peters SP, Busse WW. Asthma Exacerbations: Pathogenesis, Prevention, and Treatment. J Allergy Clin Immunol Pract. 2017;5:918–27. [DOI] [PubMed] [PMC]

Ebmeier S, Thayabaran D, Braithwaite I, Bénamara C, Weatherall M, Beasley R. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012). Lancet. 2017;390:935–45. [DOI] [PubMed]

Scenario: Newly-diagnosed asthma [Internet]. NICE; c2025 [cited 2024 Aug 31]. Available from: https://cks.nice.org.uk/topics/asthma/management/newly-diagnosed-asthma/

Aldridge RE, Hancox RJ, Cowant JO, Frampton CM, Town GI, Taylor DR. Eosinophils and eosinophilic cationic protein in induced sputum and blood: effects of budesonide and terbutaline treatment. Ann Allergy Asthma Immunol. 2002;89:492–7. [DOI] [PubMed]

Swystun VA, Gordon JR, Davis EB, Zhang X, Cockcroft DW. Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol. J Allergy Clin Immunol. 2000;106:57–64. [DOI] [PubMed]

10.

Bulletin 295: Inhaler carbon footprint [Internet]. Leeds: PrescQIPP; c2018 [cited 2024 Sep 2]. Available from: https://www.prescqipp.info/our-resources/bulletins/bulletin-295-inhaler-carbon-footprint/

11.

WMA Declaration of Helsinki – Ethical Principals For Medical Research Involving Human Participants. World Medical Association; c2024 [cited 2024 Sep 3]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki/

12.

Jorup C, Lythgoe D, Bisgaard H. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. Eur Respir J. 2018;51:1701688. [DOI] [PubMed]

13.

Rabe KF, Pizzichini E, Ställberg B, Romero S, Balanzat AM, Atienza T, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest. 2006;129:246–56. [DOI] [PubMed]

14.

Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martínez-Jimenez NE, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract. 2007;61:725–36. [DOI] [PubMed] [PMC]

15.

Nannini LJ, Neumayer NS, Brandan N, Fernández OM, Flores DM. Asthma-related hospitalizations after implementing SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen. Eur Clin Respir J. 2022;9:2110706. [DOI] [PubMed] [PMC]

16.

Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β₂-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55:1901872. [DOI] [PubMed] [PMC]

17.

Yorgancıoğlu A, Aksu K, Naycı SA, Ediger D, Mungan D, Gül U, et al.; SABINA Turkey Study Group. Short-acting β₂-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III. BMC Pulm Med. 2022;22:216. [DOI] [PubMed] [PMC]

18.

Montero-Arias F, Garcia JCH, Gallego MP, Antila MA, Schonffeldt P, Mattarucco WJ, et al. Over-prescription of short-acting β₂-agonists is associated with poor asthma outcomes: results from the Latin American cohort of the SABINA III study. J Asthma. 2023;60:574–87. [DOI] [PubMed]